Cytoselect Brdu Cell Proliferation ELISA Kit

Principle of the Assay: The CytoSelect™ BrdU Cell Proliferation ELISA Kit detects BrdU incorporated into cellular DNA during cell proliferation using an anti-BrdU antibody. When cells are incubated in media containing BrdU, the pyrimidine analog is incorporated in place of thymidine into the newly synthesized DNA of proliferating cells (Figure 1). Once the labeling media is removed, the cells are fixed and the DNA is denatured in one step with a fix/denature solution (denaturation of the DNA is necessary to improve the accessibility of the incorporated BrdU for detection). Then an anti-BrdU mouse monoclonal antibody is added followed by an HRP conjugated secondary antibody to detect the incorporated BrdU. The magnitude of the absorbance for the developed color is proportional to the quantity of BrdU incorporated into cells and can be directly correlated to cell proliferation.

Background/Introduction: The investigation of cell cycle and DNA synthesis has been essential to many fields of science. Traditionally a radiolabled thymidine has been used to track new DNA synthesis and cellular proliferation. Although quite sensitive, use of radiolabled thymidine has the limitation of having to regulate, handle and dispose of radioisotopes and often requires expensive detection equipment. More recently, the thymidine analog 5-bromo-2'-deoxyuridine (BrdU) has been used in place of radiolabled thymidine and is incorporated into newly synthesized DNA strands of actively proliferating cells. Following fixation and partial denaturation of cellular DNA, BrdU can be detected immunochemically which allows for the analysis of live cell new DNA synthesis.

1. Shoghi KI, Xu J, Su Y, He J, Rowland D, Yan Y, Garbow JR, Tu Z, Jones LA, Higashikubo R, Wheeler KT, Lubet RA, Mach RH, You M.. (2013) PLoS One. 8:e74188
2. Gong F, Wang G, Ye J, Li T, Bai H, Wang W (2013) Oncol Rep. 30:2976-2982
3. Piastowska-Ciesielska AW, Koz?owski M, Wagner W, Domi?ska K, Och?dalski T. (2013) Arch Med Sci. 30:739-744.
4. Liang XH, Li LL, Wu GG, Xie YC, Zhang GX, Chen W, Yang HF, Liu QL, Li WH, He WG, Huang YN, Zeng XC. (2013) BMC Cancer 13:412
5. Imramovský A, Jorda R, Pauk K, Rezní?ková E, Dušek J, Hanusek J, Kryštof V (2013) Eur J Med Chem 68:253-259.
Hatzis, C. et al. (2014). Enhancing Reproducibility in Cancer Drug Screening: How Do We Move Forward? Cancer Res. 74:4016-4023.

Small volumes of CytoSelect BrdU Cell Proliferation elisa kit vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS168339 is a ready-to-use microwell, strip-or-full plate ELISA (enzyme-linked immunosorbent assay) Kit for analyzing the presence of the CytoSelect BrdU Cell Proliferation, ELISA Kit target analytes in biological samples. The concentration gradients of the kit standards or positive controls render a theoretical kit detection range in biological research samples containing CytoSelect BrdU Cell Proliferation. The ELISA analytical biochemical technique of the MBS168339 kit is based on CytoSelect BrdU Cell Proliferation antibody-CytoSelect BrdU Cell Proliferation antigen interactions (immunosorbency) and an HRP colorimetric detection system to detect CytoSelect BrdU Cell Proliferation antigen targets in samples. The ELISA Kit is designed to detect native, not recombinant, CytoSelect BrdU Cell Proliferation. Appropriate sample types may include undiluted body fluids and/or tissue homogenates, secretions. Quality control assays assessing reproducibility identified the intra-assay CV (%) and inter-assay CV(%).